Discovery of a Novel Class of Phosphodiesterase 10A Inhibitors and Identification of Clinical Candidate 2-[4-(1-Methyl-4-pyridin-4-yl-1<i>H</i>-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the Treatment of Schizophrenia†Coordinates of the PDE10A crystal structures have been deposited in the Protein Data Bank for compound 1 (3HQW), 2 (3HQY), 3 (3HQW) and 9 (3HR1).
作者:Patrick R. Verhoest、Douglas S. Chapin、Michael Corman、Kari Fonseca、John F. Harms、Xinjun Hou、Eric S. Marr、Frank S. Menniti、Frederick Nelson、Rebecca O’Connor、Jayvardhan Pandit、Caroline Proulx-LaFrance、Anne W. Schmidt、Christopher J. Schmidt、Judith A. Suiciak、Spiros Liras
DOI:10.1021/jm900521k
日期:2009.8.27
By utilizing structure-based drug design (SBDD) knowledge, a novel class of phosphodiesterase (PDE) 10A inhibitors was identified. The structure-based drug design efforts identified a unique “selectivity pocket” for PDE10A inhibitors, and interactions within this pocket allowed the design of highly selective and potent PDE10A inhibitors. Further optimization of brain penetration and drug-like properties
通过利用基于结构的药物设计(SBDD)知识,鉴定了一类新型的磷酸二酯酶(PDE)10A抑制剂。基于结构的药物设计工作确定了PDE10A抑制剂的独特“选择性口袋”,并且在该口袋中的相互作用允许设计出高度选择性和有效的PDE10A抑制剂。脑渗透和类药物性质的进一步优化导致了2- [4-(1-甲基-4-吡啶-4--4-基-1 H-吡唑-3-基)-苯氧基甲基]-喹啉(PF- 2545920)。这种PDE10A抑制剂是在精神分裂症治疗中首次报道该机制的临床应用。